Holen Sie sich die Stockscreener-App
37.42
2.02%
-0.77
Handel nachbörslich:
37.42
Schlusskurs vom Vortag:
$38.19
Offen:
$38.59
24-Stunden-Volumen:
1.56M
Relative Volume:
1.41
Marktkapitalisierung:
$7.04B
Einnahmen:
$455.99M
Nettoeinkommen (Verlust:
$-285.01M
KGV:
-11.48
EPS:
-3.26
Netto-Cashflow:
$-164.61M
1W Leistung:
-6.54%
1M Leistung:
-12.71%
6M Leistung:
-17.14%
1J Leistung:
-42.04%
1-Tages-Spanne:
$37.40
$39.69
1-Wochen-Bereich:
$37.40
$41.87
52-Wochen-Spanne:
$37.40
$70.13
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Firmenname
Legend Biotech Corp Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie LEGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| LEGN | 37.42 | 7.04B | 455.99M | -285.01M | -164.61M | -3.26 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-11-06 | Eingeleitet | Goldman | Buy |
| 2023-05-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-05-22 | Eingeleitet | Daiwa Securities | Buy |
| 2023-03-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-11-02 | Eingeleitet | Evercore ISI | Outperform |
| 2022-11-01 | Eingeleitet | Cowen | Outperform |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-03-15 | Eingeleitet | Barclays | Overweight |
| 2022-01-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-07-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Legend Biotech Corp Adr Aktie (LEGN) Neueste Nachrichten
Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com
Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa
Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com
Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Legend Biotech appoints new President for CARVYKTI - Investing.com
Legend Biotech Corp ADR (NASDAQ:LEGN) Stock Is up 15.91% From Its Low, This Stock Is Just Warming Up - Stocks Register
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade - Yahoo Finance
Adma Biologics Inc (ADMA) Should Be Considered For The Next Few Weeks - Stocks Register
Legend Biotech shares hold Buy rating, $91 target despite Q3 CARVYKTI sales - Investing.com India
Legend Biotech shares hold as Barclays maintains $94 target - Investing.com India
Company’s Banking Stock: Dissecting a -18.35% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Redburn Atlantic initates Legend Biotech Corp ADR (LEGN) rating to a Buy - Knox Daily
Li Auto Inc ADR (LI) rating downgrades by Macquarie - Knox Daily
Recent Insider Activity Suggests Potential Gains for Enovix Corporation (ENVX) - Knox Daily
BMO maintains steady target on Legend Biotech on strong sales - Investing.com
BMO maintains steady target on Legend Biotech on strong sales By Investing.com - Investing.com South Africa
Stock Performance Spotlight: Legend Biotech Corp ADR (LEGN) Ends the Day at 49.68, Down by -0.64 - The Dwinnex
Legend Biotech Corp ADR’s results are impressive - US Post News
UnitedHealth, NVIDIA lead Tuesday's afternoon market cap stock movers By Investing.com - Investing.com UK
Legend Biotech maintains shares price target on steady Q3 growth - Investing.com
Legend Biotech Corp ADR’s Mixed Bag: Down -8.63% in 6 Months, Down 1.03% in 30 Days - The InvestChronicle
Market Insights: Legend Biotech Corp ADR (LEGN)’s Notable Gain of 1.62, Closing at 48.84 - The Dwinnex
Legend Biotech shares hold strong with positive outlook on robust Carvykti sales - Investing.com
Legend Biotech Corp ADR (LEGN) is a good investment, but the stock may be overvalued - US Post News
Redburn sees growth potential for Legend Biotech stock on Carvykti demand - Investing.com
Does Legend Biotech Corp ADR (LEGN) offer a good opportunity for investors? - SETE News
Legend Biotech stock maintains positive outlook with new Philadelphia R&D facility - Investing.com
Upward Trajectory: Legend Biotech Corp ADR (LEGN) Posts a Gaine, Closing at 48.68 - The Dwinnex
Legend Biotech Corp ADR (LEGN) stock analysis: A simple moving average approach - US Post News
You might want to take a look at Legend Biotech Corp ADR (LEGN) now - SETE News
Legend Biotech shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
BMO maintains Outperform rating on Legend Biotech shares on Carvykti data - Investing.com India
Legend Biotech shares maintain Buy rating from H.C. Wainwright - Investing.com India
Legend Biotech's SWOT analysis: carvykti success drives stock potential - Investing.com
Legend Biotech reiterates stock target, overweight on Phase III data - Investing.com
Legend Biotech stock poised for growth with compelling data on Carvykti - Investing.com
Legend Biotech Corp ADR (LEGN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Can you now get a good deal on Legend Biotech Corp ADR’s shares? - US Post News
There is no doubt that Legend Biotech Corp ADR (LEGN) ticks all the boxes. - SETE News
Closing Bell Recap: Legend Biotech Corp ADR (LEGN) Ends at 45.92, Reflecting a -5.38 Downturn - The Dwinnex
Analytical Lens: Exploring Legend Biotech Corp ADR (LEGN)’s Financial Story Through Ratios - The Dwinnex
What was Legend Biotech Corp ADR (LEGN)’s performance in the last session? - US Post News
European Investors Can Invest in the Future of U.S. Healthcare With This ETF - Trackinsight
Legend Biotech Corp ADR (LEGN) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Finanzdaten der Legend Biotech Corp Adr-Aktie (LEGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):